UNIRV - 2026-2 - Questão 42

TEXTBF TEXTBF GLP 1 DRUGS PROTECT AGAINST NEW OR WORSENING ADDICTIONS LARGE STUDY SHOWS PAR MARCH 4 REUTERS OZEMPIC MOUNJARO AND OTHER GLP 1 DRUGS FOR DIABETES CAN PREVENT NEW SUBSTANCE USE DISORDERS AND ALLEVIATE EXISTING ADDICTIONS ACCORDING TO FINDINGS FROM A LARGE STUDY OF U S MILITARY VETERANS PAR THE PROTECTIVE EFFECT WAS SEEN ACROSS A WIDE VARIETY OF ADDICTIVE AND HABIT FORMING SUBSTANCES INCLUDING COCAINE OPIOIDS ALCOHOL NICOTINE AND CANNABIS ADDING FURTHER EVIDENCE TO A PHENOMENON PREVIOUSLY FLAGGED IN SMALLER STUDIES PAR PAR THE 124 001 PARTICIPANTS WITHOUT A HISTORY OF SUBSTANCE ABUSE WHO WERE TAKING GLP 1 DRUGS HAD 14 LOWER ODDS OF DEVELOPING A NEW SUBSTANCE USE DISORDER OVER THE FOLLOWING THREE YEARS THAN THE 400 816 SIMILAR PATIENTS PRESCRIBED SGLT 2 INHIBITORS PAR GLP 1 DRUGS REDUCED THE ODDS OF NEW ALCOHOL USE DISORDERS BY 18 CANNABIS USE DISORDERS BY 14 COCAINE USE BY 20 NICOTINE USE BY 26 AND OPIOID USE BY 25 THE RESEARCHERS FOUND PAR AMONG 81 617 PATIENTS WITH EXISTING SUBSTANCE USE DISORDERS THE ODDS OF RELATED EMERGENCY DEPARTMENT VISITS DURING THE NEXT THREE YEARS WERE 31 LOWER FOR THOSE ON GLP 1S GLP 1 DRUGS ALSO REDUCED RELATED HOSPITAL ADMISSIONS BY 26 VERSUS THE SGLT 2S RELATED DEATHS BY 50 DRUG OVERDOSES BY 39 AND SUICIDAL IDEATION OR ATTEMPT BY 25 PAR FONTE REUTERS GLP 1 DRUGS PROTECT AGAINST NEW OR WORSENING ADDICTIONS LARGE STUDY SHOWS 4 MAR 2026 DISPONIVEL EM URL HTTP REUTERS COM BUSINESS HEALTHCARE PHARMACEUTICALS GLP 1 DRUGS PROTECT AGAINST NEW OR WORSENING ADDICTIONS LARGE STUDY SHOWS 2026 03 04 ACESSO EM 08 MAR 2026 PAR O TERMO AMONG EM AMONG 81 617 PATIENTS WITH EXISTING SUBSTANCE USE DISORDERS ESTABELECE UMA RELACAO DE BEGIN ENUMERATE LABEL ITEM A CAUSA ITEM B CONTRASTE ITEM C INCLUSAO ITEM D CONSEQUENCIA ITEM E OPOSICAO END ENUMERATE